An observational study in Chronic Kidney Disease, Kidney Transplant and Coronary Microvascular Dysfunction (CMD), sponsored by Brigham and Women's Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-30.
Sponsored by Brigham and Women's Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Renal Insufficiency, Chronic by Brigham and Women's Hospital — 4 open to participants now, 5 under way, none of them phase 3. Renal Insufficiency, Chronic · Brigham and Women's Hospital.
Among the 21 studies in Renal Insufficiency, Chronic by Brigham and Women's Hospital, this one is the only one that started in 2023, is one of 7 observational ones, and was the 20th registered.
3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.
Browse Renal Insufficiency, Chronic studies →4 of the 21 studies in Renal Insufficiency, Chronic by Brigham and Women's Hospital are open now, in 1 country. Recruiting first, the newest first:
Brigham and Women's Hospital · Sites in United States
Ages 55+ · Healthy volunteers
Brigham and Women's Hospital · Sites in United States
Ages 18+
Brigham and Women's Hospital · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is below the median of 213 across 835 observational studies indexed under Renal Insufficiency, Chronic.
Median enrollment 166 across the 14 interventional studies, 80 across the 7 observational. Of the 13 that completed or were terminated, 2 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
Brigham and Women's Hospital is the lead sponsor of 1,270 studies on the registry; 230 are open to participants now.
Of its 117 completed or terminated interventional studies of FDA-regulated products, 65 (56%) have results posted.
1 of the studies in Renal Insufficiency, Chronic by Brigham and Women's Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06051058Brigham and Women's HospitalCare Transitions App for Patients With Multiple Chronic Conditions | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 21 studies in Renal Insufficiency, Chronic by Brigham and Women's Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
People with chronic kidney disease (CKD) often experience faster aging of the heart and blood vessels, which raises the risk of heart problems beyond traditional factors like high blood pressure or cholesterol. One early sign is reduced blood flow in the tiny vessels that supply the heart, measured by a positron emission tomography (PET) scan using a marker called myocardial flow reserve (MFR). In CKD, ongoing inflammation and abnormal blood vessel growth can damage these small vessels, leading to heart stiffness and weaker heart function.
A kidney transplant offers a unique chance to study how better kidney function and reduced inflammation affect heart health. The observational RESTORE study ("Impact of Renal Transplant on Coronary Microvascular Function in Patients with Advanced CKD") will measure heart blood flow and function before and after transplant.
The study will test whether:
By understanding how kidney disease and inflammation affect the heart-and how transplant may reverse these effects-this research could help guide future treatments to better protect heart health in patients with CKD.
People with advanced kidney disease who are candidates for renal transplant will be included in the RESTORE study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients followed before and after transplant
Patients followed before transplant while on the waitlist
Stress Myocardial Blood Flow (MBF)
Myocardial blood flow with hyperemic stress measured on PET myocardial perfusion imaging
Time frame: 1. Transplant Arm: At baseline prior to transplant and one year after transplant 2. Waitlist Control Arm: At baseline prior to transplant and one year after baseline while remaining on the transplant waitlist
Myocardial Flow Reserve (MFR)
Ratio of stress and rest myocardial blood flow assessed by PET
Time frame: 1. Transplant Arm: At baseline prior to transplant and one year after transplant 2. Waitlist Control Arm: At baseline prior to transplant and one year after baseline while remaining on the transplant waitlist
Left ventricular global longitudinal strain (GLS, %)
Left ventricular global longitudinal strain measured on echocardiography
Time frame: 1. Transplant Arm: At baseline prior to transplant and one year after transplant 2. Waitlist Control Arm: At baseline prior to transplant and one year after baseline while remaining on the transplant waitlist
Left ventricular mitral inflow velocity to mitral annular early diastolic relaxation velocity ration (E/E')
E/E' measured by echocardiography
Time frame: 1. Transplant Arm: At baseline prior to transplant and one year after transplant 2. Waitlist Control Arm: At baseline prior to transplant and one year after baseline while remaining on the transplant waitlist
Interleukin-6 (IL-6) levels
IL-6 levels measured via proteomics assays
Time frame: 1. Transplant Arm: At baseline prior to transplant, and 0, 2, 4, 6 and 12 months after transplant 2. Waitlist Control Arm: At baseline prior to transplant and one year after baseline while remaining on the transplant waitlist
Vascular Endothelial Growth Factor A (VEGF-A)
VEGF-A measured by proteomic assay
Time frame: 1. Transplant Arm: At baseline prior to transplant, and 0, 2, 4, 6 and 12 months after transplant 2. Waitlist Control Arm: At baseline prior to transplant and one year after baseline while remaining on the transplant waitlist
Angiopoeitin-1 (ANGPT1) Levels
ANGPT1 levels measured by proteomic assay
Time frame: 1. Transplant Arm: At baseline prior to transplant, and 0, 2, 4, 6 and 12 months after transplant 2. Waitlist Control Arm: At baseline prior to transplant and one year after baseline while remaining on the transplant waitlist
Angiopoeitin-2 (ANGPT2) Levels
ANGPT2 levels measured by proteomics
Time frame: 1. Transplant Arm: At baseline prior to transplant, and 0, 2, 4, 6 and 12 months after transplant 2. Waitlist Control Arm: At baseline prior to transplant and one year after baseline while remaining on the transplant waitlist
Left ventricular ejection fraction (LVEF)
LVEF by echocardiography
Time frame: 1. Transplant Arm: At baseline prior to transplant and one year after transplant 2. Waitlist Control Arm: At baseline prior to transplant and one year after baseline while remaining on the transplant waitlist
High sensitivity c-reactive protein (hs-CRP)
hs-CRP measured by blood assay
Time frame: 1. Transplant Arm: At baseline prior to transplant, and 0, 2, 4, 6 and 12 months after transplant 2. Waitlist Control Arm: At baseline prior to transplant and one year after baseline while remaining on the transplant waitlist
High-sensitivity Troponin
High-sensitivity troponin by blood assay
Time frame: 1. Transplant Arm: At baseline prior to transplant, and 0, 2, 4, 6 and 12 months after transplant 2. Waitlist Control Arm: At baseline prior to transplant and one year after baseline while remaining on the transplant waitlist
Plan to share: Yes — All longitudinal human subjects data described in outcomes measures will be shared in a deidentified form. Both summarized data and individual will be shared via ClinicalTrials.gov and BioLINCC. Cardiovascular imaging data including PET and echocardiography will be shared as calculated parameters after expert interpretation from the raw images. The raw images will not be shared in a data depository, due to very large file-size, and the need for specialized software and expertise to interpret the imaging data. However, raw images may be available in a deidentified form upon appropriate and relevant request with an appropriate data transfer agreement. The protocol, sample informed consent, sample surveys, and data dictionaries will be shared on a data repository.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Start Date: June 30, 2030 End Date: Indefinite ClinicalTrials.gov and BioLINCC will make decisions about how long to preserve the data, but no deposited data has been deleted up to now.
Access criteria: All summarized and completely deidentified data on ClinicalTrials.gov will be publicly accessible without restriction. Data and metadata on the data repository BioLINCC will be controlled by standard processes at BioLINCC, including requirement for being a registered user on BioLINCC, the submission of an online request form, IRB approval, a research material distribution agreement, and approval by the NHLBI Data Repository Program Officer
No publications or documents are linked to this record.
Started Mar 2023 (actual). Primary completion is estimated for Jul 2030, 88 months after the start.
Of 276 non-industry observational studies under Renal Insufficiency, Chronic, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 192. This study's planned 88 months is above that.
Counting every sponsor, half of 327 studies reached it within 45 months; a quarter within 22 and three quarters within 191.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Renal Insufficiency, Chronic →
Brigham and Women's Hospital →